Neopharma’s pharmaceutical manufacturing facility in Bristol will keep its critical infrastructure designation even after the COVID-19 pandemic is over.
That’s according to Rep. Diana Harshbarger, who announced Thursday evening that the Cybersecurity and Infrastructure Security Agency (CISA) reaffirmed the facility’s status and said it will remain in place post-pandemic.
Original source can be found here.
